Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Laboratory Centre, NTNU - Norwegian University of Science and Technology, St. Olavs Hospital, NO-7491, Trondheim, Norway.
Department of Pathology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
Acta Neurochir (Wien). 2022 Sep;164(9):2453-2464. doi: 10.1007/s00701-022-05301-y. Epub 2022 Jul 26.
The World Health Organization (WHO) Classification of Tumours, also known as WHO Blue Books, represents an international standardised tool in the diagnostic work-up of tumours. This classification system is under continuous revision, and progress in the molecular classification of tumours in the central nervous system (CNS) enforced an update of the WHO 2016 classification, and the fifth edition, WHO CNS5, was published in 2021. The aim of this minireview is to highlight important changes in this new edition relevant for the practicing neurosurgeon.
The sixth volume of the fifth edition of the WHO Blue Books of CNS tumours and related papers formed the basis for this minireview.
Major changes encompass standardisation of tumour grading and nomenclature as well as increased incorporation of molecular markers in the classification of CNS tumours.
Advances in molecular genetics have resulted in more accurate diagnosis and prognosis of CNS tumours, and this minireview summarises important changes implemented in the last edition of WHO classification of CNS tumours important for the practicing neurosurgeon.
世界卫生组织(WHO)肿瘤分类,也称为“WHO 蓝皮书”,是肿瘤诊断工作中的一项国际性标准化工具。该分类系统正在不断修订,中枢神经系统(CNS)肿瘤的分子分类的进展要求对 2016 年 WHO 分类进行更新,第五版即 WHO CNS5 于 2021 年出版。本篇短文的目的是强调该新版中与神经外科医生的实践相关的重要变化。
该短文的基础是第五版 WHO 蓝皮书 CNS 肿瘤第六卷和相关论文。
主要变化包括肿瘤分级和命名的标准化,以及分子标志物在 CNS 肿瘤分类中的更多应用。
分子遗传学的进步使 CNS 肿瘤的诊断和预后更加准确,本文总结了在 CNS 肿瘤 WHO 分类的最新版中,对神经外科医生的实践有重要影响的重要变化。